Abstract
Objective
Supine hypertension (SH) is a feature of cardiovascular autonomic failure that often accompanies orthostatic hypotension and may represent a negative prognostic factor in parkinsonian syndromes. Here we investigated the frequency rate as well as the clinical and tilt test correlates of SH in Parkinson’s disease (PD) and multiple system atrophy (MSA).
Methods
197 PD (33 demented) and 78 MSA (24 MSA-Cerebellar, 54 MSA-Parkinsonian) patients who had undergone a tilt test examination were retrospectively included. Clinical-demographic characteristics were collected from clinical records at the time of the tilt test examination.
Results
SH (>140 mmHg systolic, >90 mmHg diastolic) occurred in 34 % of PD patients (n = 66, mild in 71 % of patients, moderate in 27 %, severe in 2 %) and 37 % of MSA ones (n = 29, mild in 55 % of patients, moderate in 17 %, severe in 28 %). No difference was observed in SH frequency between demented versus gender-, age- and disease duration-matched non-demented PD patients, or between patients with the parkinsonian (MSA-P) versus the cerebellar (MSA-C) variant of MSA. In PD, SH was associated with presence of cardiovascular comorbidities (p = 0.002) and greater systolic (p = 0.007) and diastolic (p = 0.002) orthostatic blood pressure fall. Orthostatic hypotension (p = 0.002), and to a lesser degree, lower daily dopaminergic intake (p = 0.01) and use of anti-hypertensive medications (p = 0.04) were associated with SH in MSA.
Interpretation
One-third of PD and MSA patients suffer from mild to severe SH, independently of age, disease duration or stage. In PD, cardiovascular comorbidities significantly contribute to the development of SH, while in MSA, SH appears to reflect cardiovascular autonomic failure.
Similar content being viewed by others
References
Freeman R et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21(2):69–72
Schroeder C, Jordan J, Kaufmann H (2013) Management of neurogenic orthostatic hypotension in patients with autonomic failure. Drugs 73(12):1267–1279
Velseboer DC et al (2011) Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 17(10):724–729
Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372(3):249–263
Wenning GK et al (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12(3):264–274
Low PA et al (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14(7):710–719
Fanciulli A et al (2014) Detecting nocturnal hypertension in Parkinson’s disease and multiple system atrophy: proposal of a decision-support algorithm. J Neurol
Plaschke M et al (1998) Twenty-four-hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinson’s disease and multiple system atrophy. J Hypertens 16(10):1433–1441
Jordan J et al (1999) Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol 10(1):35–42
Fanciulli A et al (2013) The potential prognostic role of cardiovascular autonomic failure in alpha-synucleinopathies. Eur J Neurol 20(2):231–235
Kim JS et al (2012) Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology 79(13):1323–1331
Pilleri M et al (2013) Cognitive and MRI correlates of orthostatic hypotension in Parkinson’s disease. J Neurol 260(1):253–259
Oh YS, Kim JS, Lee KS (2013) Orthostatic and supine blood pressures are associated with white matter hyperintensities in Parkinson disease. J Mov Disord 6(2):23–27
Lim TS et al (2009) White matter hyperintensities in patients with multiple system atrophy. J Neurol 256(10):1663–1670
Jones JD et al (2014) Influence of hypertension on neurocognitive domains in nondemented Parkinson’s disease patients. Parkinsons Dis 2014:507529
Anang JB et al (2014) Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83(14):1253–1260
Biaggioni I, Robertson RM (2002) Hypertension in orthostatic hypotension and autonomic dysfunction. Cardiol Clin 20(2):291–301 (vii)
Shannon J et al (1997) The hypertension of autonomic failure and its treatment. Hypertension 30(5):1062–1067
Pavy-Le Traon A et al (2015) New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. J Neurol Neurosurg Psychiatry (e-pub ahead of print)
Schutzman J et al (1994) Head-up tilt and hemodynamic changes during orthostatic hypotension in patients with supine hypertension. J Am Coll Cardiol 24(2):454–461
Chobanian AV et al (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42(6):1206–1252
Hughes AJ et al (2001) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. 1992. Neurology. 57(10 Suppl 3):S34–S38
Emre M et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707
Gilman S et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670–676
Tomlinson CL et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 57(1):289–300
Rose KM et al (2000) Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis risk in communities study. Am J Hypertens 13(6 Pt 1):571–578
Fedorowski A et al (2010) Orthostatic hypotension predicts incidence of heart failure: the Malmo preventive project. Am J Hypertens 23(11):1209–1215
Goldstein DS et al (2003) Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 42(2):136–142
Benarroch EE, Schmeichel AM, Parisi JE (2003) Preservation of branchimotor neurons of the nucleus ambiguus in multiple system atrophy. Neurology 60(1):115–117
Benarroch EE et al (2006) Involvement of vagal autonomic nuclei in multiple system atrophy and Lewy body disease. Neurology 66(3):378–383
Benarroch EE (2003) Brainstem in multiple system atrophy: clinicopathological correlations. Cell Mol Neurobiol 23(4–5):519–526
Davies B et al (1982) Increased numbers of alpha receptors in sympathetic denervation supersensitivity in man. J Clin Invest 69(4):779–784
Hohler AD et al (2012) Differences in motor and cognitive function in patients with Parkinson’s disease with and without orthostatic hypotension. Int J Neurosci 122(5):233–236
Allcock LM et al (2006) Orthostatic hypotension in Parkinson’s disease: association with cognitive decline? Int J Geriatr Psychiatry 21(8):778–783
Peralta C et al (2007) Orthostatic hypotension and attention in Parkinson’s disease with and without dementia. J Neural Transm 114(5):585–588
Wenning GK et al (2012) Orthostatic hypotension is differentially associated with the cerebellar versus the parkinsonian variant of multiple system atrophy: a comparative study. Cerebellum 11(1):223–226
Vanacore N et al (2000) Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology 54(1):114–119
Allam MF et al (2004) Smoking and Parkinson’s disease: systematic review of prospective studies. Mov Disord 19(6):614–621
Kollensperger M et al (2010) Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 25(15):2604–2612
Gilman S et al (2005) The North American multiple system atrophy study group. J Neural Transm 112(12):1687–1694
Study funding
This was an academic study; no external financial support was allotted.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A Fanciulli: reports no competing interests related to this article. Dr. Fanciulli received royalties from Springer Verlag and from the Massachusetts Medical Society. G. Göbel: reports no competing interests. J. P. Ndayisaba: reports no competing interests. R. Granata: reports no competing interests. S. Duerr: reports no competing interests. S. Strano: reports no competing interests. C. Colosimo: reports no competing interests related to this article. Prof Colosimo served as consultant for Ipsen, Merz and Lundbeck. W. Poewe: reports no competing interests related to this article. Unrelated to this research he reports personal fees from AbbVie, Allergan, AstraZeneca, BIAL; Boehringer-Ingelheim, Boston Scientific, GlaxoSmithKline, Ipsen, Lundbeck, Medtronic, MSD, Merck-Serono, Merz Pharmaceuticals, Novartis, Orion Pharma, Teva, UCB and Zambon (consultancies and lecture fees in relation to clinical drug development programmes for PD). Royalties: Thieme, Wiley Blackwell, Oxford University Press and Cambridge University Press. F. E. Pontieri: reports no competing interests. G.K.Wenning: reports no competing interests related to this article. Prof. Wenning served as consultant for Astra Zeneca, received lecture fees from Astra, Lundbeck, UCB and Abbvie and royalties from Cambridge University Press, Springer Verlag and from the Massachusetts Medical Society.
Ethical approval
The study received approval by the local ethical committees and was performed according to the Declaration of Helsinki.
Informed consent
For this type of study informed consent is not required.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Fanciulli, A., Göbel, G., Ndayisaba, J.P. et al. Supine hypertension in Parkinson’s disease and multiple system atrophy. Clin Auton Res 26, 97–105 (2016). https://doi.org/10.1007/s10286-015-0336-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10286-015-0336-4